Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise
Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3, the companies announced in a joint statement on Thursday.
The partnership will mark a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. India is also impacted.
A 2021 study published in the Indian Journal of Medical Biology— Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century — talks about how the ubiquitous presence and rampant spread of Shigellosis in Asian and African countries, along with the emergence of antibiotic-resistant strains, is particularly concerning.
'The scientific community must focus efforts to identify the drugs most suitable for empirical therapy according to these antibiograms. To decrease the morbidity and mortality associated with diarrhea in our country, we not only need newer antimicrobials, cost-effective vaccines but also public health measures such as safe drinking water and sanitation…,' concluded researchers in the paper.
Talking about the partnership, Bharat Biotech executive chairman Krishna Ella said, 'As the market leader in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi, Bharat Biotech is proud to partner with GSK to develop a next-generation Shigella vaccine candidate, for a severe form of bacterial diarrhoea affecting millions of children under five.'
'With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low- and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment. The use of Generalised Modules for Membrane Antigens (GMMA) technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide,' Ella added.
According to the statement issued, altSonflex1-2-3 has already shown encouraging results in early-stage clinical trials. 'A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it read.
The vaccine candidate represents one of the most advanced Shigella vaccine candidates globally. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative GMMA-based platform, and robust early clinical results.
GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system. This approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations.
As part of this agreement, Bharat Biotech will lead the further development of the vaccine candidate, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy.
'With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. With no licensed vaccines widely available, the development of our Shigella vaccine candidate, which has demonstrated promising clinical trial results, fills us with immense pride,' GSK chief global health officer Thomas Breuer said.
Having effective vaccines, which are also cost-effective, can reduce the overall disease burden significantly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Crunchy culprit: Study shows how to tackle acrylamide in French fries
Ahmedabad: That satisfying crunch in French fries and toasted sandwiches might be coming at a hidden cost. The crunch is attributed to a substance identified as acrylamide, which gives the distinct brown colour to deep-fried foods. According to several studies, the substance is linked to various gastrointestinal (GI) issues and can even lead to cancer if consumed very frequently. Research carried out at IIT Gandhinagar (IIT-Gn) addressed the issue by using amino acid adducts (AAA). The findings were published in the form of a paper titled 'Sequestration of acrylamide as amino acid-acrylamide adducts mitigates cellular stress in human gastrointestinal cell lines' recently in the journal, Food and Function, of the UK-based Royal Society of Chemistry. The authors were Axita Patel and Prof Bhaskar Datta. "Starchy foods exposed to frying, baking or roasting are vulnerable to forming acrylamide through a chemical reaction between a natural sugar (glucose) and an amino acid (asparagine). This reaction is identified as the Maillard reaction. Acrylamide is commonly found in fried potato products (French fries, chips), biscuits, toast, cookies and coffee, to name a few," said Prof Datta. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Irish homeowners eligible for solar 'bonus' if they live in these eircodes Activ8 Learn More Undo "Before its association with food, it was always associated with the chemical industry as a versatile petrochemical. " The researchers said that the rise in foods prepared at high temperatures has resulted in higher exposure to acrylamide. Acrylamide's toxic effects create oxidative stress, which affects cells in the GI tract, causing inflammation, tissue damage and even cancer. Prof Datta said that to counter acrylamide, they employed AAA. The interaction of AAA as a 'treatment agent' indicated significantly lower production of acrylamide. The team used amino acids lysine, glycine, cysteine and methionine to form stable adducts to capture acrylamide. The team is also working on sprinkle-type formulations that can be applied to raw potatoes before frying. "The study opens a new way to look at 'capturing' acrylamide to reduce its harmful effects through specific amino acids and also underlines the reason for avoiding fried starchy food not only for cholesterol but also for acrylamide. Regular consumption of antioxidants is also important," said Prof Datta. He gave a practical tip to French fries enthusiasts. "As evident in our work, a simple blanching of potatoes (briefly submerged in very hot water and then quickly cooled in ice water) before they are fried can reduce the acrylamide content," he said.
Indian Express
5 hours ago
- Indian Express
Air India crash: 251 DNA samples match, 245 bodies handed over to kin
Almost 10 days after the London-bound Air India flight with 242 persons on board plunged into a medical hostel complex in Meghaninagar moments after taking off from Ahmedabad airport on June 12, the DNA samples of 251 victims have been matched. Further, a total of 245 bodies have been handed over to the families as of Sunday evening while six families will receive the bodies shortly, said Dr Rakesh Joshi, Medical Superintendent of Ahmedabad Civil Hospital. In a video statement on Sunday evening, Dr Joshi said that the 245 victims whose bodies had been handed over included 176 Indian citizens, seven Portuguese, 49 British citizens, one Canadian and 12 on-ground persons. Since the process of matching the DNA samples is very sensitive and legal matters are also involved, this process is being completed very seriously and as fast as possible, said Dr Joshi. National Forensic Sciences University (NFSU) and forensic science laboratory (FSL) among other institutions are associated with the process. Additionally, personnel from the local administration, state Health Department and other agencies are also helping in the process. Of the 245 bodies handed over to families, 195 belong to 22 districts in Gujarat, including 24 from Vadodara, 12 from Kheda, Ahmedabad 70, Mehsana 7, Botad 1, Aravalli 3, Anand 28, Bharuch 7, Surat 12, Banaskantha 3, Gandhinagar 7, Junagadh 1, Amreli 2, Gir Somnath 5, Mahisagar 1, Bhavnagar 1, Rajkot 3, Jamnagar 2, Patan 3, Dwarka 2, and Sabarkantha 1. Further, 40 bodies were transported to other states and UTs, including Rajasthan 10, Maharashtra 13, Diu 14, Nagaland 1, Manipur 1, and Bihar 1. The mortal remains of 10 victims were sent to London by international flights, said officials.
New Indian Express
6 hours ago
- New Indian Express
‘We plan to add 1,700 beds by FY27; 57% beds likely in tier 2/3 cities'
Kochi- and Dubai-based Aster DM Healthcare, founded by Dr Azad Moopen in 1987 with a single clinic in Dubai, expects to complete the takeover of the Blackstone and TPG-backed Quality Care Hospital by the fourth quarter of this fiscal. The takeover will result in the third largest hospital chain Aster Quality Care, after Apollo and Fortis, with 38 hospitals across four brands -- Aster DM, Care Hospitals, KIMS Health and Evercare -- offering over 10,150 beds spread across 27 locations. Aster Quality Care is now jointly controlled by the Moopen family holding 24% and Blackstone owning 30.7%. In an interaction with Benn Kochuveedan of TNIE, Dr Azad Moopen shares his plans and expectations from the largest deal that his group has done. Excerpts: When do you see the merger of Quality Care Hospital getting completed? What are the targets in terms of revenue, profit expansion etc? The merger brings together four leading healthcare brands — Aster DM, Care Hospitals, KIMS Health, and Evercare — forming one of the largest hospital chains with 38 hospitals and over 10,150 beds across 27 cities. Financially, the merger strengthens the balance sheet and cash flow, enabling accelerated expansion plans. We aim to increase bed capacity to around 13,300 beds by FY27, further expanding our reach into tier 2 and 3 cities, providing a platform for sustained growth in the future. The merger is expected to be concluded by Q4FY26, with benefits expected to start flowing in from early FY27. What are the synergies you see from the merger? The merger unlocks significant synergies that will drive growth, operational efficiencies, and enhanced patient care across the combined network. Integrating our extensive hospital portfolios will allow the new entity to benefit from economies of scale by negotiating better terms with suppliers, reducing costs, and streamlining inventory management that will lower operational expenses and improve margins. What is the capex plan for fiscal 2026, especially in light of the merger-driven expansion? How many more hospitals and beds to come up this fiscal? We plan to add 1,700 beds by FY27, taking the total bed tally in India to over 6,800 through the organic route and will further look for expansion through the inorganic route. Our overall capital allocation for expansion across the domestic market is Rs 1,400 crore, of which we have already spent around Rs 350-400 crore. You have announced a Rs 850-crore investment in Kerala. What is the strategic thinking behind focusing so much on Kerala, which is often seen as a relatively mature market? Kerala is now poised for a significant transformation with a planned investment of Rs 850 crore over the next three years. This expansion will be anchored by two major greenfield projects: Aster Capital Trivandrum, a 454-bed tertiary care facility, and Aster MIMS Kasaragod, a 264-bed multispecialty hospital. In addition, our flagship hospital, Aster Medcity in Kochi, is undergoing a substantial upgrade. By FY27, our total bed capacity in Kerala is expected to reach 3,453, marking a milestone in our journey of delivering quality healthcare and driving sustainable growth. Affordable healthcare remains a chimera for the average citizen. What is Aster doing differently on this front? To balance affordability and sustainability, we centralise complex procedures in larger hospitals, while smaller units focus on primary/secondary care. By FY27, as much as 57% of our planned bed additions will be in tier 2/3 cities, reinforcing our commitment to these regions. Technology is key to bridging gaps, with telemedicine set to grow at 20.7% annually till FY30, reaching $15.1 billion. Our digital health arm is expanding tele-ICU, teleradiology, AI-driven diagnostics, IoT monitoring, and EMR platforms to enhance accessibility, affordability, and quality care nationwide. What are the digital initiatives of the group? Some of our technology-driven, patient-friendly initiatives include the introduction of the Aster Health app that offers appointment bookings, e-pharmacy, and access to digital health records. We have come up with AI-powered diagnostic solutions, including the Carpal Tunnel Syndrome detection tool in collaboration with the Indian Institute of Science. We are also expanding the home healthcare services under Aster@Home, providing in-home consultations, diagnostics, and physiotherapy, catering to India's growing elderly and chronic care populations.
